Vitasora Health Limited · ASX:VHL
Vitasora Health — Corporate Update (August 2022)
21 slides from Vitasora Health's corporate update, Aug 18, 2022
Slide 1: A Medical Devices & SaaS Company
A Medical Devices & SaaS Company DELIVERING REMOTE PATIENT MONITORING (RPM) SOLUTIONS NOW 18 August 2022 Marjan Mikel (RESPIRI CEO) Respiri Limited (ASX:RSH)
Slide 2: Forward Looking
Forward Looking Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and a
Slide 3: Executive Summary
Executive Summary Business Development continues to gain traction 1 • Major Healthcare Organisation wheezo/Access RPM customer secured that is part of a much larger healthcare provider organisation • Michigan Children’s wheezo RPM solution on track to go live in the September Quarter. • Michigan is
Slide 4: Market and macroenvironmental trends
Executive Summary Market and macroenvironmental trends Attractive USA Market Dynamic Health System Framework & Opportunities • US payors understand and fund preventative • 50M Americans living with Asthma and/or COPD. medicine to support patients whilst manage cost burden • Remote Patient Monitoring
Slide 5: 1st US Customer Focused on COPD
1st US Customer Focused on COPD Chronic Obstructive Pulmonary Disease North Carolina Customer Contracted Customer Summary: • North Carolina customer contracted through our Access Telehealth partner • Provider is part of a larger healthcare network across the North Carolina region • The larger group
Slide 6: Michigan update: Respiri's first US contracted customer
Michigan update Respiri’s first US contracted customer • Michigan Children’s Hospital, on track to start recruitment in the coming weeks • Part of a larger NYSE listed entity with $US19.5 Billion turnover healthcare services. • Operates >60 hospitals, including Michigan Children’s, and approximately
Slide 7: Business Development
Business Development Pipeline continuing to build EXAMPLES • On track to close more major deals over the next QTR, representing thousands of patient New York based hospital, part of the largest municipal healthcare system lives in the United States with $6.7 billion in annual revenues, servicing 1.4
Slide 8: USA Commercialisation Strategy…update
USA Commercialisation Strategy…update Delivered Next QTR activities USA commercial Proven &market Uniquelaunch • New customer(s) wheezo RPM contract finalisation Wheezo Completed Technology 9 months ahead of schedule • Continue to support partners with materials and collateral to further accelerate
Slide 9: Respiratory disorders place a huge burden on the US health system
Respiratory disorders place a huge burden on the US health system By the numbers; COPD is one of the most costly, estimated to total $49 billion in 2020 with those with severe COPD accounting for 3x more costs compared to those with mild disease. Those will co-morbidities, on average, cost the healt
Slide 10: Medicare Pressure on hospitals
Medicare Pressure on hospitals Re-admission targets not being met Issue & Opportunity: Pressure to find scalable population health solutions to reduce financial burden on 1000’s of hospitals • Centralised funding via CMS and Commercial Plans are available • Proven solutions able to minimise in- hosp
Slide 11: Remote Patient Monitoring
Remote Patient Monitoring Two years since codes established Remote Patient Monitoring CPT Codes2 CPT Initial set-up & patient education on equipment (one- $19.04 99453 time fee). CPT Supply of devices, collection, transmission, and report/ $55.72 99454 summary of services to the clinician. Remote ph
Slide 12: Remote Patient Monitoring (CY20)
Remote Patient Monitoring (CY20) Medicare payment (per patient) ACTUAL OPPORTUNITY USD 738.47 USD 1,303.38 MEDICARE AVE RPM CODES CLAIMED OPPORTUNITY PER PATIENT 4.34 MONTHS 7.66 MONTHS 12 MONTHS RESPIRI/ACCESS ARE UNIQUELY POSITIONED WITH THE PROPRIETARY WHEEZO SOLUTION TO ADDRESS SOME RPM PROVIDER
Slide 13: Remote Patient Monitoring: Primed and ready to deliver
Remote Patient Monitoring Primed and ready to deliver MEDICARE (CMS) AVERAGE 123% IMPROVEMENT 4.34 MONTHS COMPARED TO MEDICARE ACCESS TELEHEATLH AVERAGE 9.6 MONTHS CALENDAR YEAR 2020 12 MONTHS ACCESS TELEHEALTH RPM DELIVERS SIGNIFICANTLY HIGHER AVERAGES Pre-sales PER PATIENT COMPARED TO MEDICARE (CM
Slide 14: Sustainable and scalable solution
Sustainable and scalable solution
Slide 15: A scalable end-to-end solution
A scalable end-to-end solution Secure Cloud Storage PATIENTS HEALTHCARE PROVIDERS wheezo® respiriTM app Health Portal Healthcare Breath sensor Patient-user interface Clinical Staff Organizations FDA cleared Class II Algorithm detects abnormal breath sounds Access patient data ACOs, HMOs, Clinical
Slide 16: Health Portal
HEALTH PORTAL Secure end-to-end platform Health Programs Curated programs enabling healthcare professionals to enroll, review and better manage their patients by exception whilst in the community. Reports Program level reports allows clinical teams to review utilization and overall program metrics E
Slide 17: USA Model: Reimbursement and payment flows
USA MODEL Reimbursement and payment flows RPM partner buys wheezo devices from RSH ~USD50-USD60 RPM RESPIRI PARTNER (RSH) Distributor Manufacturer RPM partner pays RSH monthly per patient fee ~USD5-USD20 RPM partner Delivers RPM device and service to patient PHYSICIAN Physician claims PATIENT Reimbu
Slide 18: Manufacturing is Demand Ready
Manufacturing is Demand Ready Inventory built to meet USA uptake in demand in the short to 1 medium term. Australian inventory to be redirected. ~20K wheezos on hand Wheezo 4.0 to meet COGS objectives of <AUD $50 or USD 2 $35/device. Semi-conductor/ chip issue impacting all sectors has been 3 mitiga
Slide 19: On track and primed to deliver sustainable growth
On track and primed to deliver sustainable growth, underpinned by creating scalable solutions • 2 clients secured and traction continues with other clients. • Large, physician led and reimbursed market; ~50 Million patient lives with scale to reach many more in the future • Best in Class RPM partner
Slide 20: Respiri Limited Risk Factors
Disclaimer statement This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. Speculative nature of investment: An investment in Shares of
Slide 21: Thank You.
Thank You. Marjan Mikel, CEO Marjan@respiri.co +61 408 462 873 Approved for release by the Board of Respiri Limited